Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
Desmopressin was administered intranasally to seven patients with von Willebrand disease (type 1: 4 patients, type 2A: 3 patients) to assess the response and safety. von Willebrand factor antigen ranged from 8% to 60% before treatment and increased significantly after intranasal DDAVP administration (the median relative increase: two- to threefold). Factor VIII levels also increased substantially over baseline levels after intranasal administration. Before treatment ristocetin cofactor activity was 32 +/- 12% in patients with type 1 vWD and 9 +/- 5% in patients with type 2A vWD. After intranasal administration, the levels of ristocetin cofactor activity increased to 56 +/- 21% and 29 +/- 9%, respectively. The bleeding time was normalized in 86% of the patients. The abnormality of vWF multimers in type 1 vWD returned more or less to normal after intranasal DDAVP administration whereas that in type 2A vWD did not. The intranasal administration of DDAVP is safe and effective for minor bleeding episodes and is adaptable for home use in patients with type 1 and type 2A vWD.
Mohri
H
H
First Department of Internal Medicine, Yokohama City University School of Medicine, Japan.
Hashimoto
Y
Y
Yamazaki
E
E
Kanamori
H
H
Okubo
T
T
D000281:Administration, Intranasal; D001760:Bleeding Time; D003029:Coagulants / Q000008:administration & dosage; D003435:Crotalid Venoms / Q000494:pharmacology; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012310:Ristocetin / Q000494:pharmacology; D014842:von Willebrand Diseases / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000819:agonists / Q000378:metabolism
D003029:Coagulants; D003435:Crotalid Venoms; D014841:von Willebrand Factor; D012310:Ristocetin; C030961:botrocetin; D003894:Deamino Arginine Vasopressin